Roivant Sciences
Tracked across 6 events · 72 articles · First seen May 23, 2025 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Roivant Sciences announced the expansion of its brepocitinib program and the failure of Immunovant's batoclimab Phase 3 studies, which could negatively impact its stock.
Apr 02, 2026 · 16 articles
Domestic
Forbes reported on Sept. 20 that Vivek Ramaswamy, the Republican nominee for governor of United States — Ohio, is now worth an estimated $2.3 billion, up from $1.8 billion a year earlier and about $1…
Impact: Roivant Sciences is the main source of Ramaswamy's wealth, with shares near $40 and a roughly $29 billion market value after pipeline progress and the Moderna settlement. The attention reinforces its profile among biotech investors.
Sep 20, 2026 · 6 articles
Tech
Impact: Roivant Sciences is the parent company of Priovant Therapeutics. The positive trial results for brepocitinib, a key asset in its portfolio, are likely to boost investor confidence and the company's valuation.
Aug 26, 2026 · 7 articles
Tech
Immunovant announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The randomized, double-blind, placebo-controlled global study enrolled 57 adult patients who were randomized to IMVT-1402 or…
Impact: Roivant, as Immunovant's majority owner, announced the topline results and shares in the pipeline setback. Its exposure is indirect but its equity stake and pipeline narrative are affected.
Sep 23, 2026 · 7 articles
Domestic
Impact: Roivant Sciences, a subsidiary of Roivant Sciences, settled with Moderna for $2.2 billion over unauthorized use of its patents in COVID vaccines.
May 02, 2026 · 30 articles
Business
Impact: Dr. Lynn Seely previously served as president, CEO, and board member of Roivant Sciences Inc., where she commercialized innovative therapies.
Apr 20, 2026 · 6 articles
75
Roivant Sciences settled patent litigation ModernaRamaswamy $2.3B Fortune...
70
Roivant Sciences announced topline resultsImmunovant IMVT-1402 CLE Trial Miss
70
United States — Food and Drug Administration approved Lisraya Roivant SciencesRamaswamy $2.3B Fortune...
60
Roivant Sciences reported Phase 2 resultsRamaswamy $2.3B Fortune...
Organon & Co.
seller
↔
Roivant Sciences
Roivant Sciences divested its dermatology subsidiary, Dermavant Sciences, to Org
Organon & Co.
buyer
↔
Roivant Sciences
Organon & Co. acquired Dermavant Sciences, a dermatology subsidiary, from Roivan
ERGEN INTELLIGENCE
Track Roivant Sciences live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard